Navigation Links
ChromaDex® Announces Financial Results for the Year Ended 2011
Date:3/15/2012

stockholders for the fiscal year ended December 31, 2011, was $7,894,984 as compared to a net loss of $2,051,676 in 2010. The net loss in the year of 2011 was largely impacted by an increase in non-cash, share-based compensation expense related to the stock options that were granted following the May 20, 2010 private placement and other non-cash compensation. The effect of this increase, which is a "non-GAAP measure," decreased the net loss for the year of 2011 by $2,969,150 and decreased the loss per share for the year of 2011 by $0.04.

About ChromaDex®:ChromaDex, Inc., a wholly owned and operated subsidiary of ChromaDex, is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex, Inc. has an expanding pipeline of new ingredients, including its pTeroPure® (http://www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. ChromaDex recently launched its BluScience™ (http://www.bluscience.com) line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects,
'/>"/>

SOURCE ChromaDex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson
2. ChromaDex® Announces Management Changes
3. ChromaDex® Names Debra Heim as COO
4. NIAID announces 25 new awards to develop radiation countermeasures
5. Aware Announces Q3 2008 Earnings Conference Call
6. Governor Doyle announces historic genomic research collaboration
7. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
8. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
9. Parkinsons Disease Foundation announces award of $150,000
10. Jefferson Department of Surgery announces new pancreas tumor registry
11. NAS announces initiative to connect entertainment industry with top experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... standing member of the IOF Board and leading researcher ... the recipient of the prestigious Pierre Delmas Award. The ... Osteoporosis & Osteoarthritis (ESCEO13-IOF), currently being held in Rome, ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ...
... the University of Alberta are abuzz after using fruit ... caffeine,s lethal effects on cancer cellsresults that could one ... Previous research has established that caffeine interferes with ... finding that has generated interest in using the stimulant ...
... past, now has had its genome sequenced, providing a ... the adaptation from an aquatic environment to land. A ... Director of Molecular Genetics at the Benaroya Research Institute ... the University of Washington, will publish "The African coelacanth ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3
(Date:2/28/2015)... February 28, 2015 Increasing its efforts to ... launches its first three episodes of The GMO TRUTH podcast ... this month, as it continues its mission to discover the ... project's first phase, to “uncover the truth about the GMOs ... , The GMO Truth Podcast is an expansion of the ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... financial results for the quarter,ended March 31, 2008., ... net revenue of,$372.2 million compared to net revenue of ... increase was primarily due to increased,product and service revenue ...
... dynamic stabilization,nonfusion segments skyrocketed, according to Millennium Research Group,s US ... ... Millennium Research Group,s,(MRG) US Spine Marketrack(TM) results indicate that ... and surgeon,awareness and new product releases starting in Q3 2007 ...
... will be enrolled to evaluate R7128 1500mg BID in HCV,genotypes 2 and 3 prior ... ... 1:00 PM ET (US) ... CEST (Milan) --, PRINCETON, N.J. and MILAN, Italy, April 24 ,Pharmasset, Inc. (Nasdaq: ...
Cached Biology Technology:Inverness Medical Innovations Announces First Quarter 2008 Results 2Inverness Medical Innovations Announces First Quarter 2008 Results 3Inverness Medical Innovations Announces First Quarter 2008 Results 4Inverness Medical Innovations Announces First Quarter 2008 Results 5Inverness Medical Innovations Announces First Quarter 2008 Results 6Inverness Medical Innovations Announces First Quarter 2008 Results 7Inverness Medical Innovations Announces First Quarter 2008 Results 8Inverness Medical Innovations Announces First Quarter 2008 Results 9Inverness Medical Innovations Announces First Quarter 2008 Results 10Adoption of Spinal Nonfusion Technologies Doubled in One Year 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 3Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 4Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 5
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Total Canine Endostatin. Canine Cytokine ... products include a line of enzyme-linked ... reagents used for multiple research applications. ... are ultra-sensitive, quick and dependable assays. ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: